538 related articles for article (PubMed ID: 26308229)
21. Treatment patterns of long-dose-interval medication for persistent management of osteoporosis in Taiwan.
Lin SY; Chen YM; Chen WJ; Li CY; Ku CK; Chen CH; Chien LN
Arch Osteoporos; 2022 Jul; 17(1):94. PubMed ID: 35840845
[TBL] [Abstract][Full Text] [Related]
22. GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab.
Hadji P; Kyvernitakis I; Kann PH; Niedhart C; Hofbauer LC; Schwarz H; Kurth AA; Thomasius F; Schulte M; Intorcia M; Psachoulia E; Schmid T
Osteoporos Int; 2016 Oct; 27(10):2967-78. PubMed ID: 27172934
[TBL] [Abstract][Full Text] [Related]
23. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
[TBL] [Abstract][Full Text] [Related]
24. Persistence of and switches from teriparatide treatment among women and men with osteoporosis in the real world: a claims database analysis.
Usui T; Funagoshi M; Seto K; Ide K; Tanaka S; Kawakami K
Arch Osteoporos; 2018 May; 13(1):54. PubMed ID: 29725863
[TBL] [Abstract][Full Text] [Related]
25. Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
Everts-Graber J; Bonel H; Lehmann D; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T
Osteoporos Int; 2023 Nov; 34(11):1961-1973. PubMed ID: 37493978
[TBL] [Abstract][Full Text] [Related]
26. Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis.
Siris ES; Modi A; Tang J; Gandhi S; Sen S
Curr Med Res Opin; 2014 Jan; 30(1):123-30. PubMed ID: 24102262
[TBL] [Abstract][Full Text] [Related]
27. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
[TBL] [Abstract][Full Text] [Related]
28. Bisphosphonate and denosumab initiation in older adults in Ontario, Canada: a population-based cohort study.
Clemens KK; Jeyakumar N; Ouédraogo AM; Thain J; Khan T
Arch Osteoporos; 2020 Aug; 15(1):133. PubMed ID: 32816151
[TBL] [Abstract][Full Text] [Related]
29. Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
Eisman JA; Cortet B; Boolell M; Ionescu-Ittu R; Vekeman F; Heroux J; Thomasius F
Osteoporos Int; 2023 May; 34(5):977-991. PubMed ID: 36872338
[TBL] [Abstract][Full Text] [Related]
30. Using negative control outcomes to assess the comparability of treatment groups among women with osteoporosis in the United States.
McGrath LJ; Spangler L; Curtis JR; Ehrenstein V; Sørensen HT; Saul B; Levintow SN; Reams D; Bradbury BD; Brookhart MA
Pharmacoepidemiol Drug Saf; 2020 Aug; 29(8):854-863. PubMed ID: 32537883
[TBL] [Abstract][Full Text] [Related]
31. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
32. Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy.
Modi A; Siris ES; Tang J; Sen S
Curr Med Res Opin; 2015 Apr; 31(4):757-65. PubMed ID: 25661017
[TBL] [Abstract][Full Text] [Related]
33. A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System.
Devine J; Trice S; Finney Z; Yarger S; Nwokeji E; Linton A; Davies W
Osteoporos Int; 2012 Apr; 23(4):1415-24. PubMed ID: 21786005
[TBL] [Abstract][Full Text] [Related]
34. Real-world effectiveness of osteoporosis treatments in Germany.
O'Kelly J; Bartsch R; Kossack N; Borchert J; Pignot M; Hadji P
Arch Osteoporos; 2022 Aug; 17(1):119. PubMed ID: 36044096
[TBL] [Abstract][Full Text] [Related]
35. Long-term persistence in patients with osteoporosis receiving denosumab in routine practice: 36-month non-interventional, observational study.
Borek DM; Smith RC; Gruber CN; Gruber BL
Osteoporos Int; 2019 Jul; 30(7):1455-1464. PubMed ID: 31011760
[TBL] [Abstract][Full Text] [Related]
36. Utilization patterns and factors associated with persistence of new users of anti-osteoporosis treatment in Denmark: a population-based cohort study.
Pedersen AB; Risbo N; Kafatos G; Neasham D; O'Kelly J; Ehrenstein V
Arch Osteoporos; 2023 Jan; 18(1):19. PubMed ID: 36629929
[TBL] [Abstract][Full Text] [Related]
37. Drug utilization analysis of osteoporosis medications in seven European electronic health databases.
Tan EH; Robinson DE; Jödicke AM; Mosseveld M; Bødkergaard K; Reyes C; Moayyeri A; Voss A; Marconi E; Lapi F; Reinold J; Verhamme KMC; Pedersen L; Braitmaier M; de Wilde M; Ruiz MF; Aragón M; Bosco-Levy P; Lassalle R; Prieto-Alhambra D; Sanchez-Santos MT
Osteoporos Int; 2023 Oct; 34(10):1771-1781. PubMed ID: 37436441
[TBL] [Abstract][Full Text] [Related]
38. Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women.
Yusuf AA; Cummings SR; Watts NB; Feudjo MT; Sprafka JM; Zhou J; Guo H; Balasubramanian A; Cooper C
Arch Osteoporos; 2018 Mar; 13(1):33. PubMed ID: 29564735
[TBL] [Abstract][Full Text] [Related]
39. Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.
Fahrleitner-Pammer A; Papaioannou N; Gielen E; Feudjo Tepie M; Toffis C; Frieling I; Geusens P; Makras P; Boschitsch E; Callens J; Anastasilakis AD; Niedhart C; Resch H; Kalouche-Khalil L; Hadji P
Arch Osteoporos; 2017 Dec; 12(1):58. PubMed ID: 28643265
[TBL] [Abstract][Full Text] [Related]
40. Adherence to osteoporosis medications amongst Singaporean patients.
Cheen MH; Kong MC; Zhang RF; Tee FM; Chandran M
Osteoporos Int; 2012 Mar; 23(3):1053-60. PubMed ID: 21503813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
